Company Profile

Aravive, Inc. is a clinical-stage oncology company. The Company is focused on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The Company's lead product candidate, Batiraxcept, is an ultra-high affinity decoy protein that binds to GAS6, the sole ligand that activates AXL, thereby inhibiting metastasis and tumor growth, and restoring sensitivity to anti-cancer agents. Batiraxcept has been granted Fast Track Designation by the United States Food and Drug Administration (FDA) for both clear cell renal cell carcinoma and platinum-resistant ovarian cancer and Orphan Drug Designation by the European Commission in platinum-resistant recurrent ovarian cancer. Batiraxcept is in an active registrational Phase III trial in platinum-resistant ovarian cancer (NCT04729608), a Phase Ib/II trial in clear cell renal cell carcinoma (NCT04300140), and a Phase Ib/II trial in pancreatic adenocarcinoma (NCT04983407).

Employees

Sector

Biotechnology & Medical Research

More about the company

31/01/24	Aravive, Inc.(NasdaqGS:ARAV) dropped from S&P TMI Index	CI
26/01/24	Aravive, Inc.(NasdaqGS:ARAV) dropped from NASDAQ Composite Index	CI
19/01/24	Wall Street Set to Open Higher Friday Ahead of Consumer Sentiment, Home Sales Data	MT
17/01/24	Aravive Shares Sink 53% After Hours on Plans to Voluntarily Terminate Listing on Nasdaq Global Select Market	MT
17/01/24	Aravive, Inc. Announces Termination of Rudy C. Howard as Chief Financial Officer	CI
17/01/24	Aravive, Inc. Announces Termination of Gail McIntrye as Chief Executive Officer	CI
17/01/24	Aravive, Inc. Announces Board and Committee Resignations	CI
09/11/23	Aravive, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
22/08/23	Cantor Fitzgerald Downgrades Aravive to Neutral From Overweight, Adjusts Price Target to $0.25 From $18	MT
21/08/23	Aravive, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
03/08/23	Top Midday Decliners	MT
03/08/23	EF Hutton Downgrades Aravive to Hold From Buy, Adjusts Price Target to $1 From $10	MT
03/08/23	HC Wainwright Downgrades Aravive to Neutral From Buy	MT

22/08/23	Cantor Fitzgerald Downgrades Aravive to Neutral From Overweight, Adjusts Price Target to $0.25 From $18	MT
03/08/23	EF Hutton Downgrades Aravive to Hold From Buy, Adjusts Price Target to $1 From $10	MT
03/08/23	HC Wainwright Downgrades Aravive to Neutral From Buy	MT
03/08/23	William Blair Downgrades Aravive to Market Perform From Outperform	MT
03/08/23	BTIG Downgrades Aravive to Neutral From Buy	MT

17/01/24	Aravive, Inc. to Delist from The Nasdaq Stock Market	AQ
19/10/23	The Street Reports: Guide to Penny Stocks Look Now! CLNV, ARAV, RDHL, ATHX, EPAZ	AQ
02/08/23	Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer	AQ
28/07/23	Aravive to Present Updated Clinical Data from Batiraxcept Trials in Renal and Pancreatic Cancer at ESMO Congress 2023	AQ
14/07/23	Aravive to Participate in William Blair’s Innovator Series: Transitioning Biotech Breakthroughs to Commercial Success Being Held July 18, 2023	AQ

Manager	Title	Age	Since
Marek Ciszewski IRC	Investor Relations Contact	-	-
Maria Petrini PRN	Corporate Officer/Principal	-	09/04/2023

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VERSARTIS INC	-3.68%	-8.46%	-	-	2.95M
ARGENX SE	-4.14%	-8.06%	+58.96%	+118.67%	54.63B
WUXI APPTEC CO., LTD.	+1.84%	-0.66%	+75.79%	+93.87%	54.88B
INSMED INCORPORATED	-2.24%	+3.59%	+17.75%	+477.47%	25.06B
BIONTECH SE	-1.60%	-6.21%	-18.96%	-15.21%	23.14B
WUXI BIOLOGICS (CAYMAN) INC.	+2.43%	+1.06%	+47.70%	-0.11%	19.88B
GENMAB A/S	-3.19%	0.00%	+33.99%	-26.87%	17.55B
PHARMAESSENTIA CORPORATION	-6.84%	+2.18%	+195.12%	+357.18%	16.5B
EXELIXIS, INC.	-1.05%	+1.16%	+25.95%	+194.27%	14.2B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+8.74%	+3.51%	+53.81%	-	15.36B
Average	-0.97%	-0.28%	+54.46%	+149.91%	26.8B
Weighted average by Cap.	-0.91%	-1.46%	+55.34%	+139.16%

Versartis Inc Share Price Nasdaq

Stocks

US92529L1026

Biotechnology & Medical Research

Latest news : Versartis Inc

Analysts' recommendations: Versartis Inc

Press Releases: Versartis Inc

Quotes and Performance

Managers and Directors: Versartis Inc

Bio Therapeutic Drugs

Company Profile